The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Livzan M.A.

Omsk State Medical University

Gaus O.V.

Omsk State Medical University

Fecal zonulin as a biomarker of increased intestinal permeability in patients with irritable bowel syndrome (narrative review and pilot study results)

Authors:

Livzan M.A., Gaus O.V.

More about the authors

Journal: Russian Journal of Evidence-Based Gastroenterology. 2021;10(3): 47‑55

DOI: 10.17116/dokgastro20211003147

Read: 5426 times

Download PDF (RU)
Contact the author
Table of contents

FECAL ZONULIN AS A BIOMARKER OF INCREASED INTESTINAL PERMEABILITY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME (NARRATIVE REVIEW AND PILOT STUDY RESULTS)
FECAL ZONULIN AS A BIOMARKER OF INCREASED INTESTINAL PERMEABILITY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME (NARRATIVE REVIEW AND PILOT STUDY RESULTS)

To cite this article:

Livzan MA, Gaus OV. Fecal zonulin as a biomarker of increased intestinal permeability in patients with irritable bowel syndrome (narrative review and pilot study results). Russian Journal of Evidence-Based Gastroenterology. 2021;10(3):47‑55. (In Russ.)
https://doi.org/10.17116/dokgastro20211003147

Подписка 2026 Доказательная гастроэнтерология (Russian Journal of Evidence-Based Gastroenterology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Rela­tionship between inte­stinal insu­fficiency syndrome and risk of exte­rnal inte­stinal fistulas in patients with severe acute pancreatitis. Piro­gov Russian Journal of Surgery. 2025;(4):79-85
Abstract:

Current data demonstrate that intestinal barrier dysfunction is one of the key mechanisms in irritable bowel syndrome (IBS) development. Hence, assessment of intestinal permeability seems to be especially relevant for clinical practice. However, existing morphological methods are invasive and expensive, and most of the available functional tests are difficult to carry out in routine practice, require much time, and have low validity due to undefined optimal values. The need for dynamic control also limits the use of all these methods. Therefore, the search for non-invasive, highly informative biomarkers of intestinal permeability is essential. Zonulin is an endogenous analog of Vibrio cholerae toxin that can reversibly open tight junctions is being actively studied as a potential candidate. Fecal zonulin detection should be considered as a promising diagnostic test since it reflects the secretion of protein directly from the site of epithelial damage. Our pilot study demonstrated increased fecal zonulin levels in 55 patients with IBS, allowing us to confirm the possibility of using this method for the non-invasive assessment of intestinal permeability in these patients.

Keywords:

intestinal barrier
intestinal permeability
tight junction proteins
zonulin
irritable bowel syndrome

Authors:

Livzan M.A.

Omsk State Medical University

Gaus O.V.

Omsk State Medical University

Received:

10.03.2021

Accepted:

30.06.2021

Close metadata

References:

  1. Camilleri M. The Leaky Gut: Mechanisms, Measurement and Clinical Implications in Humans. Gut. 2019;68(8):1516-1526. https://doi.org/10.1136/gutjnl-2019-318427
  2. Pelaseyed T, Bergström JH, Gustafsson JK, Ermund A, Birchenough GMH, Schutte A, vander Post S, Svensson F, Rodriguez-Pineiro AM, Nyström EEL, Wising C, Johansson MEV, Hansson GC. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunological Reviews. 2014;260:8-20.  https://doi.org/10.1111/imr.12182
  3. Takeuchi K. Prophylactic effects of prostaglandin E2 on NSAID-induced enteropathy-role of EP4 receptors in its protective and healing-promoting effects. Current Opinion in Pharmacology. 2014;19:38-45.  https://doi.org/10.1016/j.coph.2014.07.005
  4. Quigley EM. Leaky gut — concept or clinical entity? Current Opinion in Gastroenterology. 2016;32:74-79.  https://doi.org/10.1097/MOG.0000000000000243
  5. Lazaridis N, Germanidis G. Current insights into the innate immune system dysfunction in irritable bowel syndrome. Annals of Gastroenterology. 2018;31(2):171-187.  https://doi.org/10.20524/aog.2018.0229
  6. Ajamian M, Steer D, Rosella G, Gibson PR. Serum zonulin as a marker of intestinal mucosal barrier function: May not be what it seems. PLoS One. 2019;14(1):e0210728. https://doi.org/10.1371/journal.pone.0210728
  7. Gaus OV, Livzan MA. IBS: what do we know about the symptoms today? Consilium Medicum. 2019;21(8):42-48. (In Russ.). https://doi.org/10.26442/20751753.2019.8.190512
  8. Fasano A. Zonulin, regulation of tight junctions, and autoimmune diseases. Annals of the New York Academy of Sciences. 2012; 1258(1):25-33.  https://doi.org/10.1111/j.1749-6632.2012.06538.x
  9. Linsalata M, Riezzo G, D’Attoma B, Clemente C, Orlando A, Russo F. Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: a case-control study. BMC Gastroenterology. 2018;18(1):167.  https://doi.org/10.1186/s12876-018-0888-6
  10. Kostenko MB, Livzan MA. The mechanisms of development of irritable bowel syndrome. Sibirskii zhurnal gastroenterologii i gepatologii. 2000;10:32. (In Russ.).
  11. Osipenko MF, Livzan MA, Skalinskaya MI, Lyalukova EA. Concentration of fecal calprotectin in differential diagnosis of intestinal diseases. Terapevticheskiy arhiv. 2015;87(2):30-33. (In Russ.). https://doi.org/10.17116/terarkh201587230-33
  12. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47:804-811.  https://doi.org/10.1136/gut.47.6.804
  13. Vanuytsel T, van Wanrooy S, Vanheel H, Vanormelingen C, Verschueren S, Houben E, Rasoel SS, Toth J, Holvoet L, Farre R, van Oudenhove L, Boeckxstaens G, Verbeke K, Tack J. Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut. 2014;63(8):1293-1299. https://doi.org/10.1136/gutjnl-2013-305690
  14. Karl JP, Margolis LM, Madslien EH, Murphy NE, Castellani JW, Gundersen Y, Hoke AV, Levangie MW, Kumar R, Chakraborty N, Gautam A, Hammamieh, Martini S, Montain SJ, Pasiakos SM. Changes in intestinal microbiota composition and metabolism coincide with increased intestinal permeability in young adults under prolonged physiological stress. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2017;312:559-571.  https://doi.org/10.1152/ajpgi.00066.2017
  15. Livzan MA, Gaus OV, Turchaninov DV, Popello DV. Abdominal pain syndrome among youth: prevalence and risk factors. Experimental’naya i klinicheskaya gastroenterologiya. 2019; 170(10):12-17. (In Russ.). https://doi.org/10.31146/1682-8658-ecg-170-10-12-17
  16. Rao AS, Camilleri M, Eckert DJ, Busciglio I, Burton DD, Ryks M, Wong BS, Lamsam J, Singh R, Zinsmeister AR. Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2011;301(5):919-928.  https://doi.org/10.1152/ajpgi.00168.2011
  17. Li J, Zhu W, Liu W, Wu Y, Wu B. Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials. Medicine (Baltimore). 2016;95(4):e2534. https://doi.org/10.1097/MD.0000000000002534
  18. Luettig J, Rosenthal R, Barmeyer C, Schulzke JD. Claudin-2 as a mediator of leaky gut barrier during intestinal inflammation. Tissue Barriers. 2015;3:e977176. https://doi.org/10.4161/21688370.2014.977176
  19. Martinez C, Lobo B, Pigrau M, Ramos L, González-Castro AM, Alonso C, Guilarte M, Gulia M, de Torres I, Azpiroz F, Santos J, Vicario M. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut. 2013;62:1160-1168. https://doi.org/10.1136/gutjnl-2012-302093
  20. Fritscher-Ravens A, Schuppan D, Ellrichmann M, Schoch S, Rocken C, Brasch J, Bethge J, Bottner M, Klose J, Milla PJ. Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology. 2014;147:1012-1020. https://doi.org/10.1053/j.gastro.2014.07.046
  21. Hayden UL, Carey HV. Neural control of intestinal ion transport and paracellular permeability is altered by nutritional status. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2000;278:1589-1594. https://doi.org/10.1152/ajpregu.2000.278.6.R1589
  22. Odenwald MA, Turner JR. Intestinal permeability defects: is it time to treat? Clinical Gastroenterology and Hepatology. 2013;11:1075-1083. https://doi.org/10.1016/j.cgh.2013.07.001
  23. Faubion WA, Camilleri M, Murray JA, Kelly P, Aadi B, Kosek MN, Larson J, Grover M, Boe G, Dyer R, Singh R. Improving the detection of environmental enteric dysfunction: a lactulose, rhamnose assay of intestinal permeability in children aged under 5 years exposed to poor sanitation and hygiene. BMJ Global Health. 2016;1(1):e000066. https://doi.org/10.1136/bmjgh-2016-000066
  24. Grover M, Camilleri M, Hines J, Burton D, Ryks M, Wadhwa A, Sundt W, Dyer R, Singh RJ. C mannitol as a novel biomarker for measurement of intestinal permeability. Neurogastroenterology and Motility. 2016;28:1114-1119. https://doi.org/10.1111/nmo.1280
  25. Shulman RJ, Jarrett ME, Cain KS, Broussard EK, Heitkemper MM. Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome. Journal of Gastroenterology. 2014;49(11):1467-1476. https://doi.org/10.1007/s00535-013-0919-6
  26. Sinagra E, Morreale GE, Mohammadian G, Fusco G, Guarnotta V, Tomasello G, Cappello F, Rossi F, Amvrosiadis G, Raimondo D. New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immune-neuroendocrine axis, motility, secretion and beyond. World Journal of Gastroenterology. 2017;23(36):6593-6627. https://doi.org/10.3748/wjg.v23.i36.6593
  27. Wadhwa A, Camilleri M, Grover M. New and Investigational Agents for Irritable Bowel Syndrome. Current Gastroenterology Reports. 2015;17:46.  https://doi.org/10.1007/s11894-015-0473-x
  28. Peoc’h K, Nuzzo A, Guedj K, Paugam C, Corcos O. Diagnosis biomarkers in acute intestinal ischemic injury: so close, yet so far. Clinical Chemistry and Laboratory Medicine. 2018;56(3):373-385.  https://doi.org/10.1515/cclm-2017-0291
  29. Adriaanse MPM, Mubarak A, Riedl RG, Ten Kate FJW, Damoiseaux JGMC, Buurman WA, Houwen RHJ, Vregdenhil ACE, Celiac Disease Study Group. Progress towards noninvasive diagnosis and follow-up of celiac disease in children; a prospective multicentre study to the usefulness of plasma I-FABP. Scientific Reports. 2017;7(1):8671. https://doi.org/10.1038/s41598-017-07242-4
  30. Bodelier AG, Pierik MJ, Lenaerts K, de Boer E, Damink SWD, Hameeteman WM, Masclee AAM, Jonkers DM. Plasma intestinal fatty acid-binding protein fails to predict endoscopic disease activity in inflammatory bowel disease patients. European Journal of Gastroenterology and Hepatology. 2016;28(7):807-813.  https://doi.org/10.1097/MEG.0000000000000616
  31. Shi H, Wan J, Liu W, Su B. An analysis for the clinical difference between post infectious irritable bowel syndrome and non post infectious irritable bowel syndrome. Zhonghua Nei Ke Za Zhi. 2015;54(4):326-329. 
  32. Honzawa Y, Nakase H, Matsuura M, Chiba T. Clinical significance of serum diamine oxidase activity in inflammatory bowel disease: importance of evaluation of small intestinal permeability. Inflammatory Bowel Diseases. 2011;17(2):23-25.  https://doi.org/10.1002/ibd.21588
  33. Xu XJ, Zhang YL, Liu L, Pan L, Yao SK. Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome: a preliminary explorative study. Alimentary Pharmacology and Therapeutics. 2017;45(1):100-114.  https://doi.org/10.1111/apt.13848
  34. Sturgeon C, Fasano A. Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases. Tissue Barriers. 2016;4(4):e1251384. https://doi.org/10.1080/21688370.2016.1251384
  35. Li C, Gao M, Zhang W, Chen C, Zhou F, Hu Z, Zeng C. Zonulin regulates intestinal permeability and facilitates enteric bacteria permeation in coronary artery disease. Scientific Reports. 2016;6:29142. https://doi.org/10.1038/srep29142
  36. Valitutti F, Fasano A. Breaking Down Barriers: How Understanding Celiac Disease Pathogenesis Informed the Development of Novel Treatments. Digestive Diseases and Sciences. 2019;64(7): 1748-1758. https://doi.org/10.1007/s10620-019-05646-y
  37. Lammers KM, Lu R, Brownley J, Gerard C, Thomas K, Rallabhandi P, Shea-Donohue T, Tamiz A, Alkan S, Netzel-Arnett S, Antalis T, Vogel SN, Fasano A. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology. 2008;135(1):194-204.  https://doi.org/10.1053/j.gastro.2008.03.023
  38. Gopalakrishnan S, Durai M, Kitchens K, Tamiz AP, Somerville R, Ginsky M, Paterson BM, Murray JA, Verdu EF, Alkan SS, Pandey NB. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides. 2012;35(1):86-94.  https://doi.org/10.1016/j.peptides.2012.02.015
  39. Leffler DA, Kelly CP, Green PH, Fedorak RN, DiMarino A, Perrow W, Rasmussen H, Wang C, Bercik P, Bachir NM, Murray JA. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015;148(7):1311-1319. https://doi.org/10.1053/j.gastro.2015.02.008
  40. Malíčková K, Francová I, Lukáš M, Kolár M, Králiková E, Bortlik M, Duricová D, Stepánková L, Zvolská K, Pánková A, Zima T. Fecal zonulin is elevated in Crohn’s disease and in cigarette smokers. Practical Laboratory Medicine. 2017;9:39-44.  https://doi.org/10.1016/j.plabm.2017.09.001
  41. Caviglia GP, Dughera F, Ribaldone DG, Rosso C, Abate ML, Pellicano R, Bresso F, Smedile A, Saracco GM, Astegiano M. Serum zonulin in patients with inflammatory bowel disease: a pilot study. Minerva Medica. 2019;110(2):95-100.  https://doi.org/10.23736/S0026-4806.18.05787-7
  42. Barbaro MR, Cremon C, Caio G, Giorgio R, Volta U, Stanghellini V, Barbara G. Zonulin serum levels are increased in nonceliac gluten sensitivity and irritable bowel syndrome with diarrhea. Gastroenterology. 2015;11:5072-5076. https://doi.org/10.1016/S0016-5085(15)30192-X
  43. Singh P, Silvester J, Chen X, Xu H, Sawhney V, Rangan V, Iturrino J, Nee J, Duerksen DR, Lembo A. Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D. United European Gastroenterology Journal. 2019;7(5):709-715.  https://doi.org/10.1177/2050640619826419
  44. Moser AM, Spindelboeck W, Halwachs B, Strohmaier H, Kump P, Gorkiewicz G, Högenauer C. Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome. European Journal of Nutrition. 2018;58(7):2767-2778. https://doi.org/10.1007/s00394-018-1826-7
  45. Akhmedov VA, Orlov IN, Gaus OV. Modern methods of rehabilitation of patients with irritable bowel syndrome. Therapiya. 2017;3(13):49-55. (In Russ.).
  46. Drapkina OM. Non-alcoholic fatty liver disease and metabolic syndrome. Spravochnik poliklinicheskogo vracha. 2008;1:45-47. (In Russ.).
  47. Fellows R, Denizot J, Stellato C, Cuomo A, Jain P, Stoyanova E, Balázsi S, Hajnády Z, Liebert A, Kazakevych J, Blackburn H, Correa RO, Fachi JL, Sato FT, Ribeiro WR, Ferreira CM, Peree H, Spagnuolo M, Mattiuz R, Matolcsi C, Guedes J, Clark J, Veldhoen M, Bonaldi T, Vinolo VMA, Varga-Weisz. Microbiota derived short chain fatty acids promote histone crotonylation in the colon through histone deacetylases. Nature Communications. 2018;9(1):105.  https://doi.org/10.1038/s41467-017-02651-5
  48. Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manchester JK, Hammer RE, Williams SC, Crowley J, Yanagisawa M, Gordon JI. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(43):16767-16772. https://doi.org/10.1073/pnas.0808567105
  49. Generoso JS, Giridharan VV, Lee J, Macedo D, Barichello T. The role of the microbiota-gut-brain axis in neuropsychiatric disorders. Brazilian Journal of Psychiatry. 2021;43(3):293-305.  https://doi.org/10.1590/1516-4446-2020-0987
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.